Astrazeneca (AZN) Short term Debt (2012 - 2026)

Astrazeneca has reported Short term Debt for 15 years, with the latest figure at $5.8 billion in Q2 2026.

• On a quarterly basis, Short term Debt fell 10.54% year-over-year to $5.8 billion in Q2 2026; TTM through Jun 2026 was $5.8 billion, a 10.54% decrease from a year earlier, with the FY2025 full-year figure at $3.1 billion, up 32.82% from the prior year.
• Short term Debt was $5.8 billion for Q2 2026 at Astrazeneca, up from -$8.0 billion in the prior quarter.
• The five-year high for Short term Debt was $6.5 billion in Q2 2025, with the low at -$8.0 billion in Q1 2026.
• Average Short term Debt over 5 years is $120.0 million, with a median of $2.2 billion recorded in 2022.
• The largest YoY upside for Short term Debt was 220.12% in 2022 against a maximum downside of 1504.2% in 2022.
• Over 5 years, Short term Debt stood at $5.3 billion in 2022, then decreased by 3.48% to $5.1 billion in 2023, then tumbled by 54.44% to $2.3 billion in 2024, then surged by 32.82% to $3.1 billion in 2025, then surged by 87.11% to $5.8 billion in 2026.
• The last three Short term Debt figures came in at $5.8 billion (Q2 2026), -$8.0 billion (Q1 2026), and $3.1 billion (Q4 2025), per Business Quant data.